Howard L Parnes

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
  2. doi request reprint Prostate cancer prevention: do the 5-ARIs make the grade?
    Howard L Parnes
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Bioeth 11:30-1. 2011
  3. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
  4. pmc Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    William L Dahut
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    BJU Int 111:1269-80. 2013
  5. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010
  6. doi request reprint Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Oncol 13:501-8. 2012
  7. pmc Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial
    Stuart G Baker
    Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892 7354, USA
    Biostatistics 11:413-8. 2010
  8. ncbi request reprint A phase II study of perifosine in androgen independent prostate cancer
    Edwin M Posadas
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:1133-7. 2005
  9. ncbi request reprint Chemoprevention in prostate cancer
    Howard L Parnes
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1533; author reply 1533. 2006
  10. doi request reprint Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial
    Douglas K Price
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 184:2297-302. 2010

Detail Information

Publications15

  1. ncbi request reprint Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
    H L Parnes
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Plaza EPN Room 2100, Rockville MD 20852, USA
    J Clin Oncol 21:1819-24. 2003
    ..To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer...
  2. doi request reprint Prostate cancer prevention: do the 5-ARIs make the grade?
    Howard L Parnes
    National Cancer Institute, Bethesda, MD 20892, USA
    Am J Bioeth 11:30-1. 2011
    ..However, to suggest that only “unambiguously safe” drugs should be approved for cancer risk reduction sets a standard that can only be met by homeopathic nostrums. That is not the standard to which we should aspire...
  3. pmc Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
    Yang Min Ning
    PharmD, Bldg 10 Rm 5A01, 10 Center Dr, Bethesda, MD 20892, USA
    J Clin Oncol 28:2070-6. 2010
    ..These results suggest that definitive clinical trials combining antiangiogenic agent combinations with docetaxel are warranted to improve treatment outcomes for patients with metastatic CRPC...
  4. pmc Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
    William L Dahut
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    BJU Int 111:1269-80. 2013
    ....
  5. pmc A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer
    William D Figg
    Clinical Pharmacology Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 183:2219-26. 2010
    ....
  6. doi request reprint Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
    Ravi A Madan
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Lancet Oncol 13:501-8. 2012
    ..We aimed to assess the safety and tolerability of ipilimumab in combination with a poxviral-based vaccine targeting prostate-specific antigen (PSA) and containing transgenes for T-cell co-stimulatory molecule expression, including CD80...
  7. pmc Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial
    Stuart G Baker
    Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892 7354, USA
    Biostatistics 11:413-8. 2010
    ..With such an important result at stake, a transparent analysis was important...
  8. ncbi request reprint A phase II study of perifosine in androgen independent prostate cancer
    Edwin M Posadas
    Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Biol Ther 4:1133-7. 2005
    ..The primary objective of this study was to determine the clinical efficacy of this agent in the treatment of androgen-independent prostate cancer (AIPC) using PSA and clinical criteria...
  9. ncbi request reprint Chemoprevention in prostate cancer
    Howard L Parnes
    Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Pharmacotherapy 26:1533; author reply 1533. 2006
  10. doi request reprint Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial
    Douglas K Price
    Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 184:2297-302. 2010
    ..We investigated the association between the length of the polymorphic trinucleotide CAG microsatellite repeats in exon 1 of the AR gene and the risk of prostate cancer...
  11. pmc Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
    Paul F Pinsky
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States
    Cancer Epidemiol 36:e401-6. 2012
    ..The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized screening trial demonstrated no mortality effect of screening. Here we analyze prostate cancer specific survival in PLCO and its relation to screening...
  12. doi request reprint Prostate cancer prevention: strategies for agent development
    Howard L Parnes
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA
    Curr Opin Oncol 25:242-51. 2013
    ..This article provides an update of clinical research supported by the National Cancer Institute's Phase I/II prostate cancer chemoprevention agent development program...
  13. doi request reprint Active surveillance for prostate cancer: past, present and future
    Eric A Singer
    Urologic Oncology Branch, Center for Cancer Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States
    Curr Opin Oncol 24:243-50. 2012
    ..This article reviews recent developments in the use of active surveillance for localized prostate cancer...
  14. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  15. pmc Challenges in clinical prostate cancer: role of imaging
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
    AJR Am J Roentgenol 192:1455-70. 2009
    ..The workshop dealt with research trends and avenues for improving imaging and applications across the clinical spectrum of the disease...